The Patent Finder

Opko Health, Inc.

18 patents currently held · Updated Nov 21, 2026
24 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
16
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 11, 2027
    The maintenance fee for Intravenous Formulations of NEUROKININ-1 Antagonists (US 9,101,615) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
  • 2 fees due Aug 2 to 16, 2027 · next Aug 2

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,563,801Pharmaceutical Formulations: Salts of 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE and Treatment Methods Using the Same
In force
 · High confidence
In forceHigh confidence
US 7,981,905Pharmaceutical Formulations: Salts of 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE and Treatment Methods Using the Same
In force
 · High confidence
In forceHigh confidence
US 8,178,550Hydrochloride Salts of 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY)-METHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE and Preparation Process Therefor
In force
 · High confidence
In forceHigh confidence
US 8,404,702Pharmaceutical Formulations:salts of 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE and Treatment Methods Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,345,692Pharmaceutical Formulations: Salts of 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE and Treatment Methods Using the Same
In force
 · Medium confidence
In forceMedium confidence
US 10,196,394Hydrochloride Salts of 8-[1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-Phenyl-1,7-Diazaspiro[4,5]DECAN-2-ONE and Preparation Process Therefor
In force
 · Medium confidence
In forceMedium confidence
US 7,709,641NK1 Antagonists
In force
 · High confidence
In forceHigh confidence
US 9,260,428Process and Intermediates for the Synthesis of 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE Compounds
In force
 · High confidence
In forceHigh confidence
US 10,000,493Process and Intermediates for the Synthesis of 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-Phenyl-1,7-Diaza-SPIRO[4.5]DECAN-2-ONE Compounds
In force
 · High confidence
In forceHigh confidence
US 7,049,320NK 1 Antagonists
In force
 · High confidence
In forceHigh confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 24 patents in force now held by others · 4 lapsed for an unpaid fee · 7 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited